Ser90

Site Information
LPGsRPGsPEREVPA SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 448827

In vivo Characterization
Methods used to characterize site in vivo:	electrophoretic mobility shift ( 29 ) , immunoassay ( 3 ) , mass spectrometry ( 2 , 4 , 5 , 6 , 7 , 9 , 11 , 12 , 14 , 15 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 29 ) , mutation of modification site ( 1 , 3 , 16 , 28 , 29 ) , phospho-antibody ( 1 , 3 , 16 ) , western blotting ( 1 , 3 , 16 )
Disease tissue studied:	bone cancer ( 16 ) , breast cancer ( 5 ) , HER2 positive breast cancer ( 2 ) , luminal A breast cancer ( 2 ) , luminal B breast cancer ( 2 ) , breast cancer, surrounding tissue ( 2 ) , breast cancer, triple negative ( 2 ) , leukemia ( 14 , 23 , 24 , 25 ) , acute lymphocytic leukemia ( 18 ) , acute myelogenous leukemia ( 14 , 24 , 25 ) , chronic myelogenous leukemia ( 23 ) , lung cancer ( 12 ) , non-small cell lung cancer ( 12 ) , melanoma skin cancer ( 6 )
Relevant cell line - cell type - tissue:	293 (epithelial) [AT1 (human), transfection] ( 22 ) , 293 (epithelial) ( 28 ) , BaF3 ('B lymphocyte, precursor') ( 16 ) , bone marrow ( 18 , 24 , 25 ) , breast ( 2 ) , BT-474 (breast cell) ( 5 ) , ES (stem) ( 28 ) , H2009 (pulmonary) ( 12 ) , H2077 (pulmonary) ( 12 ) , H2887 (pulmonary) ( 12 ) , H322M (pulmonary) ( 12 ) , HEK293T (epithelial) ( 16 ) , HeLa (cervical) ( 3 , 7 , 11 , 17 , 19 , 20 , 21 , 26 , 29 ) , Jurkat (T lymphocyte) ( 9 , 15 , 27 ) , K562 (erythroid) ( 11 , 23 ) , KG-1 (myeloid) ( 14 ) , MCF-7 (breast cell) ( 4 , 5 ) , MEF (fibroblast) ( 1 ) , Sf21 ( 29 ) , U2OS (bone cell) ( 16 ) , WM239A (melanocyte) ( 6 )

Upstream Regulation
Regulatory protein:	APP (human) ( 28 ) , Fe65 (human) ( 28 )
Putative in vivo kinases:	CDK1 (human) ( 3 , 28 ) , GSK3B (human) ( 16 )
Kinases, in vitro:	CDK1 (human) ( 29 ) , GSK3B (human) ( 16 )
Treatments:	etoposide ( 1 ) , metformin ( 4 ) , nocodazole ( 3 ) , RO-3306 ( 1 ) , seliciclib ( 3 , 28 ) , SNS-032 ( 1 )

Downstream Regulation
Effects of modification on Tip60:	acetylation ( 1 , 3 ) , enzymatic activity, induced ( 3 ) , intracellular localization ( 1 ) , phosphorylation ( 1 , 3 , 16 ) , protein stabilization ( 28 )
Effects of modification on biological processes:	cell cycle regulation ( 3 ) , DNA repair, induced ( 1 ) , transcription, altered ( 28 )

References
1	Li ML, et al. (2019) Phosphorylation of TIP60 Suppresses 53BP1 Localization at DNA Damage Sites. Mol Cell Biol 39 30297459 Curated Info
2	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
3	Mo F, et al. (2016) Acetylation of Aurora B by TIP60 ensures accurate chromosomal segregation. Nat Chem Biol 12, 226-32 26829474 Curated Info
4	Sacco F, et al. (2016) Deep Proteomics of Breast Cancer Cells Reveals that Metformin Rewires Signaling Networks Away from a Pro-growth State. Cell Syst 2, 159-71 27135362 Curated Info
5	Carrier M, et al. (2016) Phosphoproteome and Transcriptome of RA-Responsive and RA-Resistant Breast Cancer Cell Lines. PLoS One 11, e0157290 27362937 Curated Info
6	Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615 25850435 Curated Info
7	Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94 25159151 Curated Info
8	Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704 24719451 Curated Info
9	Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7 23749302 Curated Info
10	Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21 23312004 Curated Info
11	Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71 23186163 Curated Info
12	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
13	Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25 22424773 Curated Info
14	Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56 22115753 Curated Info
15	Guo A (2011) CST Curation Set: 12741; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
16	Charvet C, et al. (2011) Phosphorylation of Tip60 by GSK-3 determines the induction of PUMA and apoptosis by p53. Mol Cell 42, 584-96 21658600 Curated Info
17	Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5 21712546 Curated Info
18	Gu TL, et al. (2011) Survey of activated FLT3 signaling in leukemia. PLoS One 6, e19169 21552520 Curated Info
19	Zhou J (2010) CST Curation Set: 10708; Year: 2010; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
20	Zhou J (2010) CST Curation Set: 10685; Year: 2010; Biosample/Treatment: cell line, HeLa/nocodazole; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
21	Zhou J (2010) CST Curation Set: 10684; Year: 2010; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
22	Xiao K, et al. (2010) Global phosphorylation analysis of beta-arrestin-mediated signaling downstream of a seven transmembrane receptor (7TMR). Proc Natl Acad Sci U S A 107, 15299-304 20686112 Curated Info
23	Moritz A (2009) CST Curation Set: 8722; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
24	Gu T (2009) CST Curation Set: 7660; Year: 2009; Biosample/Treatment: tissue, bone marrow/untreated; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
25	Gu T (2009) CST Curation Set: 7659; Year: 2009; Biosample/Treatment: tissue, bone marrow/untreated; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXSP, SPXK/R) Immunoaffinity Beads Cat#: 1982 Curated Info
26	Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7 18669648 Curated Info
27	Rush J (2005) CST Curation Set: 918; Year: 2005; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XX[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) Akt Substrate Antibody Cat#: 9611 Curated Info
28	Hass MR, Yankner BA (2005) A {gamma}-secretase-independent mechanism of signal transduction by the amyloid precursor protein. J Biol Chem 280, 36895-904 16103124 Curated Info
29	Lemercier C, et al. (2003) Tip60 acetyltransferase activity is controlled by phosphorylation. J Biol Chem 278, 4713-8 12468530 Curated Info